Impact of EXOPULSE Mollii Suit on Fibromyalgia: Double-Blind Randomized Study
Overview
This double-blind, randomized, sham-controlled crossover study evaluated the effects of the EXOPULSE Mollii Suit on fibromyalgia patients. Results demonstrated significant improvements in fibromyalgia impact, pain, and quality of life following active stimulation compared to sham, with sustained benefits observed in an open-label extension.
Background
Fibromyalgia is a prevalent musculoskeletal disorder characterized by widespread pain, fatigue, and reduced quality of life. Conventional pharmacological treatments provide limited relief, prompting interest in non-pharmacological approaches such as transcutaneous electrical nerve stimulation (TENS). However, traditional TENS devices target limited body regions, which may be insufficient for fibromyalgia's widespread symptoms. The EXOPULSE Mollii Suit, a full-body garment with multiple electrodes, offers a novel approach by stimulating numerous muscle groups simultaneously to potentially alleviate fibromyalgia symptoms.
Data Highlights
Outcome
Baseline (Mean ± SD)
Post-Active Intervention (Mean ± SD)
Statistical Significance
FIQtotal Score
66.06 ± 13.46
50.81 ± 23.22
Friedman’s P < .01, Dunn’s P < .05
Phase 1 Sham Intervention
Not significant change
Not significant change
NS
Secondary Measures (Pain Catastrophizing, QoL domains)
Improved post-active intervention
Improved post-active intervention
Significant
Phase 2 Open-Label Extension
Continued improvement in FIQtotal and secondary outcomes
Continued improvement
Significant
Key Findings
Active EXOPULSE Mollii Suit stimulation for 2 weeks significantly reduced fibromyalgia impact as measured by FIQtotal scores.
No significant improvements were observed following the sham stimulation phase.
Secondary outcomes including pain catastrophizing and quality of life domains showed significant improvement after active treatment.
Open-label extension of 4 weeks demonstrated sustained benefits in fibromyalgia impact, depression, anxiety, and quality of life.
No severe adverse events were reported, indicating good tolerability of the intervention.
Clinical Implications
The EXOPULSE Mollii Suit represents a promising home-based neuromodulation therapy for fibromyalgia, offering clinically meaningful improvements in disease impact and related symptoms. Its full-body stimulation capability may address the widespread pain characteristic of fibromyalgia more effectively than conventional TENS devices. Clinicians should consider this modality as a complementary treatment option, pending further large-scale validation.
Conclusion
This study supports the efficacy and safety of the EXOPULSE Mollii Suit in reducing fibromyalgia symptoms and improving quality of life. These findings align with prior research and underscore the potential of full-body electrical stimulation as a novel therapeutic approach for fibromyalgia.
References
Riachi et al. 2024 -- Impact of the EXOPULSE Mollii Suit on Fibromyalgia Patients: Results from a Double-Blind, Randomized Sham-Controlled Study (EXOFIB2)
